New Market Report: Aveo Pharmaceuticals, Inc.: PharmaVitae Report

New Pharmaceuticals market report from Datamonitor: "Aveo Pharmaceuticals, Inc.: PharmaVitae Report"
By: Fast Market Research, Inc.
 
 
Spread the Word
Listed Under

Tags:
Aveo
Tivozanib
2012-17

Industry:
Medical

Location:
Massachusetts - US

Oct. 8, 2012 - PRLog -- This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Scope
* Patient-based forecasts for Aveo's lead candidate, tivozanib, supported by key opinion leader research
* Assessment of Aveo's corporate strategy, operating performance, and earlier-stage pipeline

Highlights

Aveo's lead candidate is tivozanib, a small molecule oral angiogenesis inhibitor. Its primary indication (for which it plans to seek US approval) is in metastatic renal cell carcinoma, but Aveo is also developing the drug for colorectal cancer and breast cancer.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/464846_aveo_pharmaceuticals_inc_pharmavitae_report.aspx
------------------------------------------------------------

Aveo plans to submit a New Drug Application for tivozanib in the third quarter of 2012, while commercialization partner Astellas will submit a Marketing Authorization Application to the European Medicines Agency in the second half of 2012.

Reasons to Get this Report
* Evaluate the potential of Aveo's Phase III oncology product, tovozanib
* Assess the potential of the company's earlier-stage pipeline of novel antibodies

Report Table of Contents:

ABOUT THIS REPORT

* PharmaVitae Explorer database
* Chapter structure

* Sales and product analysis
* Financial analysis

* Data sourcing

* Analyst consensus

EXECUTIVE SUMMARY

* Company introduction

* Recent developments
* Corporate relationships

* Strategic overview
* SWOT analysis

* Strengths
* Weaknesses
* Opportunities
* Threats

SALES AND PRODUCT ANALYSIS

* Sales overview
* Product analysis

* Product sales

* Tivozanib

* Targeted therapies provide much-needed therapeutic options in RCC
* Sutent (sunitinib; Pfizer)
* Nexavar (sorafenib; Bayer/Onyx)
* Votrient (pazopanib; GlaxoSmithKline)
* Inlyta (axitinib; Pfizer)
* Combinations of targeted therapies may be increasingly used
* Clinical trials
* Factors affecting approval and use
* Key forecasting assumptions

* Other products

* AV-203

FINANCIAL ANALYSIS

* Financial performance overview

* Operating costs and profit analysis, 2006-11
* Operating costs and profit analysis, 2012-17

APPENDIX

* References
* Exchange rates

TABLES

* Table: Key Aveo corporate relationships
* Table: Aveo key product sales, by region ($m), 2012-17
* Table: Aveo's Phase III clinical trial program in RCC
* Table: Tivozanib US sales forecast model
* Table: Tivozanib EU sales forecast model
* Table: Aveo operating revenue/cost analysis ($m), 2006-11
* Table: Aveo operating revenue/cost analysis ($m), 2012-17
* Table: Exchange rates, 2011

FIGURES

* Figure: PharmaVitae Explorer
* Figure: Aveo prescription pharmaceutical performance, sales ($m) and growth rate (%), 2012-17
* Figure: Aveo key product sales ($m), 2012-17
* Figure: Aveo operating/cost performance ($m), 2004-16

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002
End
Email:***@fastmr.com Email Verified
Phone:1.800.844.8156
Zip:01267
Tags:Aveo, Tivozanib, 2012-17
Industry:Medical
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research PRs
Trending News
Most Viewed
Top Daily News

Most Viewed
Top Daily News
PTC News

Oct 08, 2012 News



Like PRLog?
9K2K1K
Click to Share